

Contents

Appendix A: Acknowledgments 1

Appendix B: Evidence on Hormone Replacement Therapy and Fractures 5

References 17

Appendix C: Evidence on HRT and Bone Loss 19

Conclusions 30

References 31

Appendix D: Summary of Hip Fracture Prediction Methods 35

Requirements of the OTA Hip Fracture Prediction Model 35

Measuring Bone Mass 35

Predicting Bone Mass Over Time 36

Relationship of Bone Mass to Hip Fracture Risk 44

References 47

Appendix E: Hormonal Replacement Therapy Regimens 49

Estrogen Dosing Regimens 49

Therapy with PERT 53

Acute Indications for HRT 54

Evaluation and Followup of Women Taking HRT 55

Compliance with HRT 56

References 59

Appendix F: Evidence on Breast Cancer and Hormonal Replacement Therapy 65


Biological Plausibility 65

Case-Control Studies 66

Cohort Studies 67

Clinical Trials 68

Combined Estrogen-Progestin Therapy and Breast Cancer Risk 68



Stage of Breast Cancer at Diagnosis in HRT Users Versus Nonusers	70
Breast Cancer Mortality in HRT Users Versus Nonusers	71
Conclusions	72
References	73

Appendix G: Evidence on HRT and Endometrial Cancer 111

Duration and Dose of Estrogen	112
Recency of Use of Estrogen	112
Stage and Grade of Endometrial Cancer	112
Estrogen Use and Survival from Endometrial Cancer	114
Estrogen/Progestin Replacement Therapy	115
Implications for OTA's Cost Effectiveness Model	117
References	118

Appendix H: Evidence on HRT and Gallbladder Disease 159

References	165
------------	-----

Appendix 1: Evidence on HRT and Coronary Heart Disease 167

How Estrogen May Affect CHD	167
Evidence on ERT and CHD	168
Evidence on PERT and CHD	189
Conclusions	191
References	193

Appendix J: Methods for Estimating costs 201

BMD Screening Cost	201
HRT Cost	201
Cost of Heart Disease	204
Cost of Hip Fracture	205
Cost of Cholecystectomy	205
Breast Cancer Costs	205
Endometrial Cancer Costs	207
References	210

Appendix K: Abbreviations and Glossary 211